The term “non-alcoholic steatohepatitis” (NASH) was originally used to describe liver damage characterized by lobular inflammation, steatosis and ballooning of hepatocytes. In addition, a large proportion of patients were described as having “cryptogenic cirrhosis” at the time: The term “non-alcoholic fatty liver disease” (NAFLD) was established as the diagnosis for these patients.
Autoren
- PD Dr. med. Sena Blümel
- Prof. Dr. med. Christoph Jüngst
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Focus on prevention
Colorectal cancer screening – an update
- COPD therapy
Drug therapy – Update 2025
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Chronic and acute coronary syndrome
Proactive and evidence-based decision-making
- Pediatric multiple sclerosis